What is “Sohonos”?
“Sohonos” is a brand name associated with a prescription treatment for adults with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy. It is taken by mouth and is designed to address the production of a disease-causing protein involved in amyloid formation. [1]
What does Sohonos treat?
Sohonos is used for hATTR amyloidosis with polyneuropathy in adults. This condition involves abnormal deposition of amyloid in the nervous system, leading to progressive nerve-related symptoms. [1]
How is Sohonos taken (and how long)?
The provided information does not include dosing instructions or treatment duration. If you share the specific context you mean by “Sohonos” (for example, your country, the exact product label, or what you want to know: dose, timing, or side effects), I can help narrow it down. [1]
What side effects are associated with Sohonos?
The provided information does not list side effects. If you paste the relevant label text or tell me what concerns you most (common side effects, serious risks, or drug interactions), I can respond more precisely. [1]
Is Sohonos the only drug for this condition?
The provided information only identifies Sohonos; it does not compare it with other therapies for hATTR amyloidosis with polyneuropathy. If you tell me which competitor or alternative you have in mind, I can compare based on the available sources. [1]
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/